MediPharm Labs Corp.
LABS.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 25.51% | 31.88% | 47.64% | 57.50% | 67.51% |
| Total Depreciation and Amortization | 16.82% | 13.71% | 8.05% | -15.90% | -53.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 118.01% | 75.44% | -249.11% | -242.29% | -126.30% |
| Change in Net Operating Assets | 40.29% | 2.36% | -12.28% | -13.02% | -13.56% |
| Cash from Operations | 83.57% | 64.39% | 22.46% | 26.89% | 33.59% |
| Capital Expenditure | 65.66% | 37.24% | 38.28% | 46.78% | 17.40% |
| Sale of Property, Plant, and Equipment | -61.16% | -- | 35,438.18% | 28,074.55% | 262.77% |
| Cash Acquisitions | -100.00% | -100.00% | -- | -- | -- |
| Divestitures | -29.51% | -29.51% | -29.51% | -29.51% | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -42.65% | 2.34% | 41.58% | 34.35% | 3,128.03% |
| Total Debt Issued | -25.12% | -29.80% | -20.43% | -20.43% | -20.43% |
| Total Debt Repaid | -43.88% | 41.33% | -43.35% | -112.13% | -339.51% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -18.23% | -12.95% | 961.07% | 42.93% | 63.29% |
| Cash from Financing | -252.49% | 119.04% | 1,612.92% | -141.50% | -140.92% |
| Foreign Exchange rate Adjustments | -73.61% | -179.00% | -224.92% | -293.24% | -150.26% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 102.19% | 116.39% | 61.56% | 42.42% | 66.55% |
